Verbesserte Verfahren zur Herstellung eines Lipidierten Proteins

Details

Veröffentlichungs-Nr.

EP4751733

Anmeldetag

9. April 2021

Veröffentlichung

3. Juni 2026

Rechtsraum

EP

IPC

A61K39/215

Abstract

The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.GS) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).

Anmelder

Firma

Valneva Austria GmbH

Land

🇦🇹 Österreich

Fachgebiete